Should you buy these stocks too? What would it take to make you feel wealthy? Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more! (RTTNews.com) - Pfizer Inc. ( PFE ) announced top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ or tofacitinib citrate 5mg twice daily or BID in the treatment of moderate to severe rheumatoid arthritis or RA. ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint. There were three comparisons, which found: XELJANZ 5mg plus MTX met its primary endpoint in demonstrating non-inferiority versus Humira plus MTX; XELJANZ 5mg monotherapy did not meet its primary endpoint of non-inferiority versus Humira plus MTX or versus XELJANZ plus MTX. The RA clinical development program has over 20 clinical trials and to-date represents more than 21,100 patient-years of drug exposure. The long-term extension program, spanning over eight years of safety experience, is one of the largest in the RA category with respect to number of patients and patient-years of exposure. For comments and feedback: contact editorial@rttnews.com http://www.rttnews.com Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages. You have selected to change your default setting for the Quote Search. This will now be your default target page;
					unless you change your configuration again, or you delete your
					cookies. Are you sure you want to change your settings? Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.